Merck chief concerned over future U.S. biopharma innovation

Merck ($MRK) CEO Kenneth Frazier has weighed in on some of the U.S. biopharmaceutical industry's most pressing issues in an opinion piece in the Wall Street Journal. He warns that weak protections on drug patents, drug pricing policies and the high cost of drug development threaten the global leadership of the U.S. biopharma industry. The op-ed calls on policymakers to take actions that would support further innovation in biopharma. Item

Suggested Articles

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics’ CEO Aron Knickerbocker is exiting the company.

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…